Dr Carla Martins

University of Cambridge

University departments
MRC Cancer Unit
University institutes
Hutchison MRC Research Centre

Position: Group leader
Personal home page: http://www.mrc-cu.cam.ac.uk/research/carla-martins-folder

PubMed journal articles - click here

Dr Carla Martins is pleased to consider applications from prospective PhD students.

Research description

Modelling tumour development and therapy
The main aim of our programme is to define the molecular and functional alterations that enable lung tumour progression from benign stages to high-grade adenocarcinoma. While our immediate goal is to improve the targeting of tumours harbouring particular sets of mutations, our ultimate goal is to identify broader and targetable signatures associated with benign and advanced disease. We are currently focused on the evolution of lung tumours expressing mutant versions of Kras and p53.

Despite being two of the most frequent mutations in human lung adenocarcinoma, how each of these key alterations contributes to malignant progression remains unclear. To address these key questions our lab uses a multidisciplinary approach that combines the generation of genetically modified tumour models that closely recapitulate the evolution of the human disease to “omics” approaches, microscopy and in-vivo imaging.

Research Programme
Aerodigestive Cancer
Tumour type interests
Lung
cm666
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge


Key publications

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Kerr EM, Gaude E, Turrell FK, Frezza C, Martins CP. Nature. 2016 Mar 3;531(7592):110-3. doi: 10.1038/nature16967. Epub 2016 Feb 24.

From tumor prevention to therapy: Empowering p53 to fight back. Frezza C, Martins CP. Drug Resist Updat. 2012 Oct;15(5-6):258-67. doi: 10.1016/j.drup.2012.10.001.

Validation of MdmX as a therapeutic target for re-activating p53 in tumors. Garcia D, Warr MR, Martins CP, Brown Swigart L, Passegué E, Evan GI. Genes & Development.Genes Dev. 2011 Aug 15;25(16):1746-57. doi: 10.1101/gad.16722111.

Selective activation of p53-mediated tumour suppression in high-grade tumours.Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, Martins CP. Nature. 2010 Nov 25;468(7323):567-71.

Modeling the therapeutic efficacy of p53 restoration in tumors. Martins CP, Brown-Swigart L, Evan GI. Cell. 2006 Dec 29;127(7):1323-34.